Trial reportScientific reports2025
Study on the efficacy of fractional CO
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and vaginal microbiota effects of oral Lactobacillus crispatus M247 combined with vaginal laser therapy in menopausal women with atrophic vulvovaginitis: a prospective, randomized and controlled study.Lasers in medical science · 2026Trial
- Fractional COLasers in surgery and medicine · 2026Article
- Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To investigate the efficacy and mechanisms of fractional CO2 laser treatment for Vaginal Relaxation Syndrome (VRS) combined with recurrent bacterial vaginitis. Patients with VRS and recurrent bacterial vaginitis were randomly assigned to an intervention group (n = 60) receiving fractional CO2 laser therapy in addition to metronidazole, or a control group (n = 60) receiving metronidazole alone. Post-treatment assessments included vaginal relaxation, vaginal health index (VHI) scores, lactobacilli distribution, vaginal pH, recurrence rates, and the correlation between lactobacilli distribution and VHI. (1) Vaginal relaxation improved significantly in the intervention group compared to both pre-treatment and the control group (P = 0.000). (2) VHI scores and lactobacilli distribution improved in both groups post-treatment, with significantly higher scores in the intervention group (P = 0.000). (3) The intervention group exhibited a significantly lower vaginal pH compared to pre-treatment and the control group (P = 0.001). (4) Recurrence rates were significantly lower in the intervention group (8.33%) compared to the control group (36.67%) (P = 0.000). A strong positive correlation was found between lactobacilli distribution and VHI in the intervention group (r = 0.79, P < 0.001). Fractional CO2 laser combined with conventional therapy improves VRS and recurrent bacterial vaginitis outcomes, reduces recurrence, and enhances vaginal microecology.Trial registration: Chinese Clinical Trial Registry, Registration number ChiCTR2400094125.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.